These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 16895221

  • 1. [Anti-atherosclerotic effect].
    Takai S, Miyazaki M.
    Nihon Rinsho; 2006 Jul; 64 Suppl 5():518-23. PubMed ID: 16895221
    [No Abstract] [Full Text] [Related]

  • 2. Cellular basis for therapeutic choices in heart failure.
    Opie LH.
    Circulation; 2004 Oct 26; 110(17):2559-61. PubMed ID: 15505109
    [No Abstract] [Full Text] [Related]

  • 3. [New findings with RAS inhibitors in diabetic nephropathy].
    Ito S.
    Nihon Jinzo Gakkai Shi; 2007 Oct 26; 49(5):485-90. PubMed ID: 17695809
    [No Abstract] [Full Text] [Related]

  • 4. [The renin-angiotensin system].
    Hilgers KF.
    Urologe A; 2009 Aug 26; 48(8):925-33; quiz 934-5. PubMed ID: 19669119
    [No Abstract] [Full Text] [Related]

  • 5. Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?
    McMurray JJ, Pfeffer MA, Swedberg K, Dzau VJ.
    Circulation; 2004 Nov 16; 110(20):3281-8. PubMed ID: 15545527
    [No Abstract] [Full Text] [Related]

  • 6. Novel therapies blocking the renin-angiotensin-aldosterone system in the management of hypertension and related disorders.
    Krum H, Gilbert RE.
    J Hypertens; 2007 Jan 16; 25(1):25-35. PubMed ID: 17143168
    [Abstract] [Full Text] [Related]

  • 7. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y, Nagasawa Y, Tomida K, Mikami S, Kaneko T, Okada N, Tsubakihara Y, Imai E, Shoji T.
    Hypertens Res; 2008 Jan 16; 31(1):59-67. PubMed ID: 18360019
    [Abstract] [Full Text] [Related]

  • 8. [Is it always necessary to use triple combination in the treatment of patients with chronic cardiac failure? Choice of the third neurohormonal blocker].
    Belenkov IuN, Mareev VIu, Skvortsov AA.
    Ter Arkh; 2008 Jan 16; 80(9):5-12. PubMed ID: 19555028
    [No Abstract] [Full Text] [Related]

  • 9. [Effect of combination therapy with angiotensin II type I receptor and aldosterone receptor blockers in heart failure].
    Aoyama N.
    Nihon Rinsho; 2007 May 28; 65 Suppl 5():145-9. PubMed ID: 17569312
    [No Abstract] [Full Text] [Related]

  • 10. Use of antagonists of aldosterone in patients with chronic kidney disease: Potential advantages and risks.
    Campese VM, Park J.
    J Hypertens; 2006 Nov 28; 24(11):2157-9. PubMed ID: 17053534
    [No Abstract] [Full Text] [Related]

  • 11. [Atrial fibrillation: potential therapeutic interventions in the renin-angiotensin-aldosterone system].
    Dabrowski R, Szwed H.
    Kardiol Pol; 2007 Apr 28; 65(4):440-5. PubMed ID: 17530565
    [No Abstract] [Full Text] [Related]

  • 12. [Renin-angiotensin system as a potential target for the treatment with heart failure: ACE inhibitors, angiotensin-II receptor blockers and aldosterone antagonists].
    Sanada S, Kitakaze M.
    Nihon Rinsho; 2003 May 28; 61(5):821-6. PubMed ID: 12755009
    [Abstract] [Full Text] [Related]

  • 13. Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker.
    Chrysostomou A, Pedagogos E, MacGregor L, Becker GJ.
    Clin J Am Soc Nephrol; 2006 Mar 28; 1(2):256-62. PubMed ID: 17699214
    [Abstract] [Full Text] [Related]

  • 14. Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: a clinical review.
    Duprez DA.
    J Hypertens; 2006 Jun 28; 24(6):983-91. PubMed ID: 16685192
    [Abstract] [Full Text] [Related]

  • 15. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in hypertension due to primary aldosteronism: a case for exclusion.
    Bubbar CD, Blackburn DF, Wilson MP, Wilson TW.
    Ann Pharmacother; 2007 Jan 28; 41(1):129-32. PubMed ID: 17179189
    [Abstract] [Full Text] [Related]

  • 16. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
    Makkar KM, Sanoski CA, Spinler SA.
    Pharmacotherapy; 2009 Jan 28; 29(1):31-48. PubMed ID: 19113795
    [Abstract] [Full Text] [Related]

  • 17. AT1 receptor blockade for the prevention of cardiovascular events after myocardial infarction.
    Azadpour M, Lamas GA.
    Expert Rev Cardiovasc Ther; 2004 Nov 28; 2(6):891-902. PubMed ID: 15500434
    [Abstract] [Full Text] [Related]

  • 18. Aliskiren combined with losartan in diabetes and nephropathy.
    Lindner T.
    N Engl J Med; 2008 Sep 04; 359(10):1068-9; author reply 1069-70. PubMed ID: 18777612
    [No Abstract] [Full Text] [Related]

  • 19. Aldosterone blockade over and above ACE-inhibitors in patients with coronary artery disease but without heart failure.
    Shah NC, Pringle S, Struthers A.
    J Renin Angiotensin Aldosterone Syst; 2006 Mar 04; 7(1):20-30. PubMed ID: 17083070
    [Abstract] [Full Text] [Related]

  • 20. [Protective effect of ARB on vascular diseases].
    Kim-Mitsuyama S.
    Nihon Rinsho; 2006 Jul 04; 64 Suppl 5():475-81. PubMed ID: 16895216
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.